Masters Pharmaceuticals Ltd, a Elstree UK-based specialist international supplier and distributor of pharmaceutical products, has received a £2.65m investment from Albion Ventures.
Masters operates primarily in the international supply of licensed drugs into unlicensed territories providing access for international markets to drugs that are commonly available in the US and Europe but hard to access from outside those markets. Other activities are centred on specialist wholesale distribution of generic and branded pharmaceuticals.
The proceeds from the investment will enable the company to continue to expand in its core markets of Latin America, the Middle East and the Caribbean and open new markets in Asia.
In conjunction with the investment, Masters has appointed Bill Burns as non-executive chairman of its Board. Mr Burns, who brings to the company over 40 years of experience in the sector, most recently served as CEO of Roche Pharmaceuticals.